



THE NATIONAL
HEMOPHILIA FOUNDATION

RECEIVED

J. D. RYAN

July 14, 1982

To: NHF Chapter Presidents

From: Charles J. Carman, President *CJC/c3*

Re: Attached Patient Alert

The attached Patient Alert is intended to provide you with advance information concerning a report that will be made in the Center For Disease Control July 16 issue of Morbidity and Mortality Weekly Report about a potential risk to hemophiliacs. It is important for you to understand and communicate that this information is preliminary in nature at this time.

Further, even if the preliminary speculation is confirmed, CDC does not recommend any changes in treatment regimen at this time.

I have been invited to meet with Dr. Harry M. Meyer, Jr., Director, National Center for Drugs & Biologics of the Food and Drug Administration, on July 16. Dr. Louis Aledort, Medical Co-Director of the Foundation has been requested to serve on a "blue ribbon" panel concerning this matter. Dr. Aledort will be communicating to treaters throughout the country with a medical bulletin.

You can be assured that your NHF will continue its up-to-date interaction with CDC, FDA, NIH, Plasma Industry and others to make sure that our interests are represented. We will keep you informed on a timely basis of all new developments. We have also made arrangements with Dr. Bruce L. Evatt, Director Division of Host Factors (Center For Infectious Diseases, Center For Disease Control), to attend our Annual Meeting in Kansas City. He will address this issue as part of our program, "Issues Facing Hemophiliacs."

We urge that the attached Patient Alert announcement be printed in chapter bulletins and circulated to all hemophiliacs, health professionals and other interested parties.

Please feel free to refer all media inquiries to the National Office.

CJC:bg

19 WEST 34th STREET • SUITE 1204 • NEW YORK, NEW YORK 10001 • (212) 563-0211

UNH004 007-1

100 2737

M004005 S